Theravance Biopharma (TBPH) Other Non-Current Liabilities (2013 - 2026)

Theravance Biopharma (TBPH) has reported Other Non-Current Liabilities for 14 consecutive years, with $244000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 81.04% year-over-year to $244000.0; the TTM figure through Mar 2026 stood at $244000.0 (down 81.04% YoY), while the FY2025 annual figure was $313000.0, down 99.63% from the prior year.
• Other Non-Current Liabilities fell to $244000.0 in Q1 2026 per TBPH's latest filing, from $313000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $83.7 million in Q4 2024 and bottomed at $244000.0 in Q1 2026.
• Historically, Other Non-Current Liabilities has averaged $20.5 million across 5 years, with a median of $5.0 million in 2024.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 2301.72% — and 2025, when it tumbled 99.63%.
• Theravance Biopharma's Other Non-Current Liabilities stood at $76.0 million in 2022, then gained by 4.57% to $79.5 million in 2023, then climbed by 5.32% to $83.7 million in 2024, then sank by 99.63% to $313000.0 in 2025, then decreased by 22.04% to $244000.0 in 2026.
• Business Quant data shows TBPH's Other Non-Current Liabilities at $244000.0 in Q1 2026, $313000.0 in Q4 2025, and $313000.0 in Q3 2025.